Ainsling Capital Raises $280M For Latest Life Sciences Fund

Nov 3 2017 | 10:45pm ET

New York-based life sciences private equity company Aisling Capital has raised $280 million capital commitments for its latest fund to focus on bringing breakthrough medical treatments to market.

With the new fund, Aisling will assist companies developing therapeutics to complete their clinical studies, navigate approval and ultimately reach commercialization, the company said. 

The company’s prior fund raised $650 million in 2009.

“Today, every biotech company must develop treatments that generate significant upside for patient care through profound impact on disease, fewer side effects, and a shift away from toxic therapies toward a personalized approach,” said Steve Elms, co-managing partner of Aisling Capital, in a statement. “We are pleased to have the resources to continue to be a significant participant in our market and help the companies we invest in achieve this goal.”

Founded in 2000, Aisling Capital led by Elms and co-managing partner Andrew Schiff, M.D. The company invests in public and private late-stage pharma, biotech, medtech and service companies across a variety of investment structures, and has raised over $1.8 billion in committed capital across four funds since inception. 


In Depth

Q&A: Decathlon Capital On Revenue-Based Alternative Lending

Oct 30 2017 | 3:49pm ET

The explosion in private credit activity since the end of the financial crisis is...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

CAIS: How Technology is Disrupting the Alternative Investment Industry

Nov 7 2017 | 5:35pm ET

If there’s one thing that alternative investment professionals can agree on, it...